Chris Boshoff: the U.S. FDA approved our targeted combination therapy for the treatment of adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
Chris Boshoff , Chief Oncology Research and Development Officer and Executive Vice President at Pfizer, shared on LinkedIn:
“Today, we announced the U.S. FDA approved our targeted combination therapy for the treatment of adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC), marking an important moment for the NSCLC community. Read more here.
There are many types of cancer biomarkers, including genetic mutations that can affect how cancer cells grow, multiply, disseminate and die. By pursuing precision medicines that target a patient’s specific genetic type of cancer, we are following the science to help address the underlying cause of disease.
At Pfizer, we continue to build on our deep understanding of BRAF V600-mutant cancers to bring new treatment options to patients in need. We look forward to helping more people through our targeted combination therapy.”
For the video attached to the post click here.
Source: Chris Boshoff/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023